For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > ARCHIVE
ARCHIVE
- Press Seminar
July 29, 2002
- Fukujin Agrees on Prices with Only 20% of Hospitals by End of June
July 29, 2002
- Takara Bio to Develop New Gene Detection System with Nanosphere
July 29, 2002
- Taiyo Pharm Beefs Up Contract Manufacturing Business
July 29, 2002
- Roche Diagnostics: Simple Blood Glucose Determination System, Accu-Chek Active
July 29, 2002
- BUSINESS NEWS IN BRIEF
July 29, 2002
- Eiken, Sysmex Tie Up to Market Urinarysis System in China
July 29, 2002
- Major Domestic Firms Feel Cool to Pfizer's Move
July 29, 2002
- InCROM Establishes EuCROM to Handle CRO Business in Europe
July 29, 2002
- CORPORATE ROUNDUP NEWS IN BRIEF
July 29, 2002
- MEDICAL DEVICE NEWS IN BRIEF
July 29, 2002
- 4.3% of ex-Koseisho Officials Were Aware of Risk of Hepatitis Due to Fibrinogen
July 29, 2002
- Korosho to Set Examples in Reform
July 22, 2002
- GL for Treatment of Esophageal Cancer Prepared
July 22, 2002
- REGULATORY NEWS IN BRIEF
July 22, 2002
- Shortage of Pharmacists Unlikely: Korosho Survey
July 22, 2002
- Aiming to Become Agile, Nimble Innovative Drug Firm: Mr Kannan of Allergan
July 22, 2002
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
July 22, 2002
- Kyowa Hakko Pharma Business to Focus on Cancer, Allergy
July 22, 2002
- 11 of 15 Major Firms Introduce Researchers Rewarding Programs: Survey
July 22, 2002
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…